adamantane has been researched along with Parkinson Disease in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Grieb, P; Rejdak, K | 1 |
| Abdallah, DM; Al-Shorbagy, MY; Arab, HH; Nassar, NN | 1 |
| Avakian, GN; Katunina, EA; Nerobkova, LN; Petrukhova, AV; Saiadian, KhS; Val'dman, EA; Voronina, TA | 1 |
| Cenci, MA; Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Kapitsa, IG; Kovalev, GI; Voronina, TA; Zimin, IA | 1 |
| Kurushina, OV; Rybak, VA; Sarycheva, TN | 1 |
| Alekseev, KV; Bastrygin, DV; Kolyvanov, GB; Litvin, EA; Zherdev, VP | 1 |
| Crossman, AR; Kobylecki, C; Ravenscroft, P | 1 |
| Codd, R; Crouch, PJ; Ganio, G; Liddell, JR; Liu, J; Mok, SS; Obando, D; Volitakis, I; White, AR | 1 |
| Oleĭnik, LI | 1 |
| Dodel, RC; Oertel, WH | 1 |
| Bédard, PJ; Blanchet, PJ; Britton, DR; Grondin, R; Shiosaki, K | 1 |
| Andrén, PE; Ekesbo, A; Gunne, LM; Sonesson, C; Tedroff, J | 1 |
| Greulich, W; Schäfer, D | 1 |
| Dette-Wildenhahn, G; Fellehner, H; Wesemann, W | 1 |
1 review(s) available for adamantane and Parkinson Disease
| Article | Year |
|---|---|
Effects of parkinsonian medication on sleep.
Topics: Adamantane; Antiparkinson Agents; Cholinergic Antagonists; Dopamine Agents; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Sleep; Sleep Wake Disorders | 2000 |
2 trial(s) available for adamantane and Parkinson Disease
| Article | Year |
|---|---|
[The possibilities of using himantane in the treatment of Parkinson's disease].
Topics: Adamantane; Aged; Antiparkinson Agents; Drug Administration Schedule; Electroencephalography; Female; Humans; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Tremor | 2008 |
[Ladasten in the management of non-motor symptoms of Parkinson's disease].
Topics: Adamantane; Aged; Female; Humans; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2011 |
12 other study(ies) available for adamantane and Parkinson Disease
| Article | Year |
|---|---|
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Cognitive Dysfunction; Coronavirus Infections; COVID-19; Dopamine Agents; Female; Humans; Male; Memantine; Middle Aged; Multiple Sclerosis; Pandemics; Parkinson Disease; Pneumonia, Viral; Protective Factors; SARS-CoV-2; Severity of Illness Index | 2020 |
Saxagliptin: a novel antiparkinsonian approach.
Topics: Adamantane; Animals; Antiparkinson Agents; Body Weight; Brain; Cathepsin C; Cyclic AMP; Dipeptides; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Gene Expression Regulation; Insecticides; Lipid Peroxidation; Male; Nerve Tissue Proteins; NF-E2-Related Factor 2; Parkinson Disease; Rats; Rats, Wistar; Rotenone; Tyrosine 3-Monooxygenase | 2015 |
Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Topics: Adamantane; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Brain; Calcium; Callithrix; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2010 |
[Effects of subchronic hemantane administration on dopamine and serotonin receptors in intact and MPP+-treated rat brain ex vivo].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Corpus Striatum; Disease Models, Animal; Hippocampus; Male; MPTP Poisoning; Neurotoxins; Parkinson Disease; Parkinson Disease, Secondary; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D1 | 2010 |
[Pharmacokinetics of hemantane in rats].
Topics: Adamantane; Animals; Antiparkinson Agents; Biological Availability; Biotransformation; Brain Chemistry; Chromatography, Liquid; Feces; Humans; Injections, Intraperitoneal; Injections, Intravenous; Male; Parkinson Disease; Rats; Rats, Inbred Strains; Tandem Mass Spectrometry; Tissue Distribution | 2011 |
Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adamantane; Alternative Splicing; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Iodine Isotopes; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, AMPA; RNA, Messenger; Sympatholytics | 2013 |
Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease.
Topics: Adamantane; Animals; Astrocytes; Benzoates; Cells, Cultured; Deferasirox; Deferoxamine; Dopaminergic Neurons; Humans; Hydrogen Peroxide; Iron Chelating Agents; Mice; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Permeability; Substantia Nigra; Triazoles | 2013 |
[Vascular parkinsonism and current methods for its drug treatment].
Topics: Adamantane; Aged; Humans; Intracranial Arteriosclerosis; Levodopa; Middle Aged; Parasympatholytics; Parkinson Disease | 1984 |
International guide to drugs for Parkinson's disease.
Topics: Adamantane; Cholinergic Antagonists; Dopamine Antagonists; Histamine Antagonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 1995 |
Dopamine D1 receptor desensitization profile in MPTP-lesioned primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Animals; Benzopyrans; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Locomotion; Macaca; Parkinson Disease; Receptors, Dopamine D1 | 1996 |
Motor effects of (-)-OSU6162 in primates with unilateral 6-hydroxydopamine lesions.
Topics: Adamantane; Animals; Apomorphine; Benzazepines; Benzopyrans; Callithrix; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Quinpirole; Rotation | 2000 |
In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson.
Topics: Adamantane; Amantadine; Animals; Biological Transport; Bridged-Ring Compounds; Electric Stimulation; Kinetics; Male; Parkinson Disease; Rats; Serotonin; Synapses; Synaptic Membranes; Synaptic Vesicles; Synaptosomes | 1979 |